COHERUS ONCOLOGY INC (CHRS) Stock Price & Overview
NASDAQ:CHRS • US19249H1032
Current stock price
The current stock price of CHRS is 1.73 USD. Today CHRS is down by -0.57%. In the past month the price decreased by -1.7%. In the past year, price increased by 121.28%.
CHRS Key Statistics
- Market Cap
- 259.31M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.36
- Dividend Yield
- N/A
CHRS Stock Performance
CHRS Stock Chart
CHRS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CHRS. When comparing the yearly performance of all stocks, CHRS is one of the better performing stocks in the market, outperforming 93.38% of all stocks.
CHRS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CHRS. While CHRS is still in line with the averages on profitability rating, there are concerns on its financial health.
CHRS Earnings
On March 9, 2026 CHRS reported an EPS of -0.34 and a revenue of 12.75M. The company beat EPS expectations (2.91% surprise) and missed revenue expectations (-10.37% surprise).
CHRS Forecast & Estimates
12 analysts have analysed CHRS and the average price target is 5.78 USD. This implies a price increase of 234.11% is expected in the next year compared to the current price of 1.73.
For the next year, analysts expect an EPS growth of 28.3% and a revenue growth 64.8% for CHRS
CHRS Groups
Sector & Classification
CHRS Financial Highlights
Over the last trailing twelve months CHRS reported a non-GAAP Earnings per Share(EPS) of -1.36. The EPS decreased by -81.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 398.43% | ||
| ROA | 65.04% | ||
| ROE | 275.39% | ||
| Debt/Equity | 0.84 |
CHRS Ownership
CHRS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CHRS
Company Profile
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 147 full-time employees. The company went IPO on 2014-11-06. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
Company Info
IPO: 2014-11-06
COHERUS ONCOLOGY INC
333 Twin Dolphin Dr, Suite 600, 201 Redwood Shores Parkway, Suite 200
Redwood City CALIFORNIA 94065 US
CEO: Dennis M. Lanfear
Employees: 228
Phone: 13026587581
COHERUS ONCOLOGY INC / CHRS FAQ
What does COHERUS ONCOLOGY INC do?
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 147 full-time employees. The company went IPO on 2014-11-06. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
What is the current price of CHRS stock?
The current stock price of CHRS is 1.73 USD. The price decreased by -0.57% in the last trading session.
Does CHRS stock pay dividends?
CHRS does not pay a dividend.
What is the ChartMill rating of COHERUS ONCOLOGY INC stock?
CHRS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for CHRS stock?
12 analysts have analysed CHRS and the average price target is 5.78 USD. This implies a price increase of 234.11% is expected in the next year compared to the current price of 1.73.
Can you provide the number of employees for COHERUS ONCOLOGY INC?
COHERUS ONCOLOGY INC (CHRS) currently has 228 employees.
What is COHERUS ONCOLOGY INC worth?
COHERUS ONCOLOGY INC (CHRS) has a market capitalization of 259.31M USD. This makes CHRS a Micro Cap stock.